Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: Assessment of relapse during a 6-month, multisite, open-label study

Philip G. Janicak*, Ziad Nahas, Sarah H. Lisanby, H. Brent Solvason, Shirlene M. Sampson, William M. McDonald, Lauren B. Marangell, Peter Rosenquist, W. Vaughn McCall, James Kimball, John P. O'Reardon, Colleen Loo, Mustafa H. Husain, Andrew Krystal, William S Gilmer, Sheila M. Dowd, Mark A. Demitrack, Alan F. Schatzberg

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

128 Scopus citations

Fingerprint

Dive into the research topics of 'Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: Assessment of relapse during a 6-month, multisite, open-label study'. Together they form a unique fingerprint.

INIS

Neuroscience